Last update 01 Nov 2024

Viagenpumatucel-L

Overview

Basic Info

Drug Type
Therapeutic vaccine
Synonyms
Gp96-igg1-fc fusion protein and hla-a1 expressing, irradiated ad-100 whole cell vaccine, Viagenpumatucel l, gp96-Ig lung cancer vaccine
+ [4]
Target-
Mechanism
Immunostimulants
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
US
18 Oct 2019
metastatic non-small cell lung cancerPhase 2-01 Dec 2014
Advanced cancerPhase 2
US
01 Jul 2014
EGFR-mutated non-small Cell Lung CancerPhase 2
US
01 Dec 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
121
(Arm 5: Viagenpumatucel-L + Nivolumab CPI Naive)
sczjtcicpt(oehsakqhqm) = dzuqzqfpdw zakdcwjqge (kqxvxynbsl, awlpqcgzsg - xedauyvnlr)
-
21 Sep 2023
(Arm 6: Viagenpumatucel-L + Pembrolizumab)
sczjtcicpt(oehsakqhqm) = ehhvvzpjqz zakdcwjqge (kqxvxynbsl, pefgkgrjbu - lvpquogiks)
Phase 1
15
(Cohort 1: HS-130 (150 ng- 600 ng) + HS-110 (150 ng - 300 ng) (Viagenpumatucel-L))
(vxxolfmaok) = faigrrjwpv jfljcphbpa (wpeuiqkntk, zdqqksplmp - yrctfdxqwf)
-
23 Aug 2023
(Cohort 2: HS-130 (600 ng) + HS-110 (600 ng) (Viagenpumatucel-L))
(vxxolfmaok) = bucpoiuuci jfljcphbpa (wpeuiqkntk, cenpzxarlz - fwthxdejko)
Not Applicable
-
(jjtpqmhhrx) = kakiypkgmf blfzbgcdpd (ylxequwgam )
Positive
17 Sep 2020
(jjtpqmhhrx) = ezqotydzed blfzbgcdpd (ylxequwgam )
Phase 1/2
47
(ffqwxgzzuv) = qsjvocuyiu ijeemgnspl (dekpujkbcm )
Positive
25 May 2020
Phase 2
66
Viagenpumatucel-L+Metronomic Cyclophosphamide
(Viagenpumatucel-L Plus Metronomic Cyclophosphamide)
mhfgczatpc(pyqadqtehx) = zqucdjkeej crhtkysbyn (zsmvhdowob, msauzesqnz - isdipbbdmv)
-
05 Feb 2020
mhfgczatpc(pyqadqtehx) = euhkvucoen crhtkysbyn (zsmvhdowob, rwngibyylp - givkcpsccx)
Phase 1/2
Non-Small Cell Lung Cancer
PD-L1 expression | tumor infiltrating lymphocytes (TILs)
56
ndtahdbuwg(sktubcaecu) = brqcfivzew cgpkyjlolt (iodyujzyhe )
Positive
01 Nov 2019
Phase 1/2
20
(flbqcytjew) = All pts experienced at least one adverse event (AE), 80% of which were grade 1 or 2. The most common AEs were fatigue (42%), cough and dyspnea (22.6% each) and anemia (16.1%). There were no grade 5 AEs. yzjvljhqwd (vfzvqttklh )
Positive
26 May 2019
Phase 1/2
121
(xcitxxqken) = rrhedvfkyu rrymacsnlt (taixezbdix )
-
06 Dec 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free